CEO Today USA Awards 2021

42 CEO of Amgen About Robert A. Bradway Robert A. Bradway is Amgen’s chairman and chief executive officer. He became chairman in January 2013 and chief executive officer in May 2012. Bradway served as the company’s president and chief operating officer from May 2010 to May 2012, and was appointed to the Amgen Board of Directors in October 2011. He joined the company in 2006 as vice president, Operations Strategy, and served as executive vice president and chief financial officer fromApril 2007 to May 2010. Prior to joining Amgen, Bradway was a managing director at Morgan Stanley in London where, beginning in 2001, he had responsibility for the firm’s banking department and corporate finance activities in Europe. He joined Morgan Stanley in New York as a health care industry investment banker in 1985 and moved to London in 1990. Bradway is a member of the board of directors of The Boeing Company, chairing its Finance Committee and serving on its Audit committee. He also serves as a board member of the W. M. Keck Foundation, the Pharmaceutical Research and Manufacturers of America (PhRMA), and the CEO Roundtable on Cancer, a non- profit organization dedicated to advancing cancer treatment and prevention. In addition, Bradway serves on the board of trustees of the University of Southern California, and he is a member of the American Heart Association CEO Roundtable, which is helping the Association meet its goal of improving the cardiovascular health of all Americans. Bradway holds a bachelor’s degree in biology from Amherst College and a master’s degree in business administration from Harvard University. About Amgen Our belief—and the core of our strategy—is that innovative, highly differentiated medicines that provide large clinical benefits in addressing serious diseases are medicines that will not only help patients, but also will help reduce the social and economic burden of disease in society today. Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology innovator since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential. Our Values Be Science-Based Our success depends on superior scientific innovation, integrity and continuous improvement in all aspects of our business through the application of the scientific method. We see the scientific method as a multi-step process that includes designing the right experiment, collecting and analyzing data and rational decision making. It is not subjective or emotional, but rather a logical, open and rational process. Applying the scientific method in all parts of the organization is expected and highly valued. Robert A. Bradway CAL I FORN I A

RkJQdWJsaXNoZXIy Mjk3Mzkz